In today's announcement, Astraveus SAS ("Astraveus" or the "Company"), a company that has created microfluidic, modular cell foundries that have revolutionized the manufacturing of cell and gene therapy (CGT), announces Michel Spagnol's appointment as its new Chairman of Board. This new member joins existing Board members Jérémie Laurent, CEO, Alain Huriez, Director of AdBio Partners, Christian Ulrich, Director of M Ventures, Fiona MacLaughlin, Director of JJDC, and Laurent Higueret, Director of BPI France Large Venture.
It is Michel, a Stanford PhD graduate, who brings a wealth of experience and expertise to Astraveus.. Michel has many years of international experience in the healthcare industry and over the course of his career has demonstrated his ability to successfully lead the transformation of multiple advanced technologies into a significant industrial and commercial success.. During his tenure at Novasep, an international CDMO group based in France (now part of the Axplora group), he successfully led the restructuring of the Novasep group, increasing its value to €1 billion as a result of the restructuring..There are five billion people in the world. As part of his tenure at Astraveus, he oversaw the development of the company's gene therapy franchise into a world-renowned CDMO, which led to its divestiture to Thermos Fischer Scientific Group in 2021, giving him a strong understanding of its target market.. In the past, he held leadership roles at Rhodia Pharma Solutions and Shasun Pharma Solutions. Currently, Michel serves as the Deputy Chairman of the Board of Directors at Axplora Group, and as Chairman of the Strategic Assessment Board at MVG Group.. Besides that, he is the Founder and President of Mifani-Invest, a venture focused on investments in healthcare and digital transformation.
Besides that, he is the Founder and President of Mifani-Invest, a venture focused on investments in healthcare and digital transformation.
According to Jerémie Laurent, Founder and Chief Executive Officer of Astraveus, "Michel's leadership will prove vital in helping us accelerate the development of our Lakhesys platform and commercialization." It is our belief that our microfluidic cell foundries will revolutionize the manufacturing of cell and gene therapies, and Michel's expertise and track record will assist us in successfully bringing these therapies to patients. It will be a pleasure to welcome him to Astraveus and to work with him.
As the newly appointed Chairman of Astraveus' Board of Directors, Michel Spagnol said, "The groundbreaking Lakhesys platform has great potential for advancing the manufacturing of cell and gene therapies. I am very excited to work with the Lakhesys team to drive innovation in this area and play a part in successfully bringing more gene therapies into clinics."
In an ongoing effort to revolutionize the field of CGT manufacturing, Astraveus is introducing its LakhesysTM platform, an end-to-end cell foundry that combines deep process optimization and single-use, microfluidic bioprocessors to produce better results with fewer inputs and lower costs.. Using CGT manufacturing technology, Astraveus is seeking to significantly increase patient access to these life-changing therapies by eliminating the need for large-scale infrastructure, reducing costs and processing times, and overcoming the logistical challenges associated with CGT manufacturing.. An investment of €16 million was recently completed by the Company.The company received a seed financing of $5 million to significantly advance the development of its technology and expand its team
The company received a seed financing of $5 million to significantly advance the development of its technology and expand its team
Astraveus: What we do
We at Astraveus are developing the next generation of manufacturing solutions for cell and gene therapy (CGT). With its cell foundries, Astraveus has become a leading company in the field of miniaturizing and automating cell and gene therapy manufacturing in a unique, modular, end-to-end, microfluidic solution that mimics the elegance of natural systems. Through the deep process optimization of the platform, the system enables greater precision, which increases the probability of reproducing optimal manufacturing methods in a more cost-efficient manner, using fewer materials and reducing the environmental impact when delivering better therapies.. With the full potential of cell and gene therapies restricted today by high costs and limited throughput, this transformative solution has the potential to enable a therapeutic revolution at scale, thereby allowing these lifesaving therapies to be made accessible to the many thousands of patients throughout the world who desperately need them.. Astrageus is a Paris-based company that was founded in 2016 by Jérémie Laurent at the St Louis Hospital. The company is supported by AdBio partners, M Ventures, Johnson & Johnson Innovation - JJDC Inc, and Bpifrance Large Ventures.
Astrageus is a Paris-based company that was founded in 2016 by Jérémie Laurent at the St Louis Hospital. The company is supported by AdBio partners, M Ventures, Johnson & Johnson Innovation - JJDC Inc, and Bpifrance Large Ventures.
Our company, Astraveus, is part of the #FrenchTech2030, a program run by La French Tech, which ensures that high-ranking French institutions such as the Secrétariat Général Pour l'Investissement, BPIFrance, and for healthcare companies, the Agence de l'Innovation en Santé, provide the company with support.
Astraveus is the source of the information
Astraveus SAS ("Astraveus" or the "Company") is the creator of modular, microfluidic cell foundries that have revolutionized the field of cell and gene therapy (CGT)...
This is a description of the company, Astraveus SAS ("Astraveus" or "the Company"), a manufacturer of modular, microfluidic cell foundries that are transforming cell and gene therapy (CGT)...
If you'd like PRN's top stories and curated news delivered to your inbox every week, sign up now!

Source prnewswire